Prognostic and safety analysis of capecitabine monotherapy versus CapeOx (capecitabine plus oxaliplatin) in elderly patients with high-risk stage II and stage III MRD-negative colorectal cancer.

ABSTRACT:

Background

Postoperative adjuvant chemotherapy is a cornerstone of treatment for high-risk stage II and stage III colorectal cancer (CRC). However, the optimal regimen for elderly minimal residual disease (MRD)-negative patients remains controversial. This study aimed to compare the efficacy and safety of capecitabine monotherapy versus the CapeOx regimen (capecitabine plus oxaliplatin) in this population.

Methods

We conducted a retrospective analysis of 117 elderly patients (aged 65-85 years) with high-risk stage II and stage III CRC who underwent curative surgery and tested MRD-negative. Patients were divided into two groups based on postoperative chemotherapy: capecitabine monotherapy (n=58) and CapeOx (n=59). Baseline characteristics, disease-free survival (DFS), 3-year

SUBMITTER: Zhai J 

PROVIDER: S-EPMC12598343 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature